Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Outperform to Market Perform. There are 2,432 funds or ...

Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad ...

In addition to Truist Financial, Regeneron also received a Buy from Oppenheimer’s Matthew Biegler in a report issued today. However, on January 28, Leerink Partners maintained a Hold rating on ...

Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a report on Wednesday. Leerink Partners ...

Leerink cuts Regeneron stock price target to $762 from $880 Open in App ...